Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P61278 (
somatostatin
)
22,083
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The second child of healthy unrelated parents presented with chronic diarrhoea since the age of two months, initially associated with non-characteristic liver involvement. Recurrent infections, severe failure to thrive and various metabolic deficiencies complicated the further course, as well as profuse watery diarrhoea with elevated regulatory gut peptides, responding only to
somatostatin
analog treatment. At 22 months of age, intermittent cholestasis with permanently normal serum
gamma-glutamyltransferase
was evident. The child died of fulminant purulent meningitis at the age of three years six months. Liver histology showed intrahepatic cholestasis, bile duct paucity with focal proliferation as well as slight portal and intralobular fibrosis. The clinical, biochemical and histopathological findings were indicative of Byler's disease.
...
PMID:Progressive idiopathic cholestasis presenting with profuse watery diarrhoea and recurrent infections (Byler's disease). 139 94
Glutathione content and
glutamyl transpeptidase
activity in different regions of adult female rat brain were determined at 10 and 30 min following intraventricular injection of LHRH and
somatostatin
. Hypothalamic glutathione levels were significantly elevated at 10 and 30 min after a single injection of a 0.1 micrograms dose of LHRH. On the contrary, glutathione levels significantly decreased in the hypothalamus, cerebral cortex and cerebellum at 10 and 30 min after 0.5 or 1 microgram dose. However, significant decrease in brain stem glutathione was evident at 30 min after 0.5 microgram and 10 min after the 1 microgram dose.
Somatostatin
at doses of 0.5 microgram and 1 microgram significantly decreased glutathione levels in all four brain regions both at 10 and 30 min following injection into the 3rd ventricle. Gamma-glutamyl transpeptidase activity in the hypothalamus and cerebral cortex was significantly elevated after intraventricular injection of LHRH. However, a significant increase in
gamma-glutamyl transpeptidase
activity in cerebellum and brain stem was seen only with 0.5 and 1 micrograms doses of LHRH.
Somatostatin
also significantly increased
gamma-glutamyl transpeptidase
activity in hypothalamus, cerebral cortex, brain stem and cerebellum. The decrease in glutathione levels with corresponding increase in
gamma-glutamyl transpeptidase
activity after intraventricular administration of LHRH and
somatostatin
suggests a possible interaction between glutathione and hypothalamic peptides.
...
PMID:Glutathione and gamma-glutamyl transpeptidase in the adult female rat brain after intraventricular injection of LHRH and somatostatin. 197 5
Twenty patients undergoing sphincteroplasty for cholelithiasis were randomly divided into two groups of 10. The former (T) were treated with a 4-h
somatostatin
intravenous drip (250 micrograms/h), started at the beginning of operation, while the latter (C) made up the control group. Serum and urine amylase, amylase creatinine clearance ratio, and liver function tests were assessed for 2 days before surgery, after the operation and for a period of 5 postoperative days. Homogeneity between the two series was verified in experimental conditions. Statistical differences occurred postoperatively in amylase creatinine clearance ratio, which proved higher in C group, and
gamma-GT
, which was higher in T group. Short-term
somatostatin
administration proved effective in reducing the postoperative amylase creatinine clearance ratio, although more evident results are reported after long-term administration. Cholestasis or any serious impairment in liver function did not occur, suggesting the suitability of
somatostatin
use even in patients with jaundice. Since a relationship between postoperative amylase levels and risk of pancreatitis has not yet been proved, the value of
somatostatin
in the prevention of postoperative pancreatitis after sphincteroplasty needs to be further verified.
...
PMID:Effect of perioperative somatostatin administration of sphincteroplasty-induced increase of amylase. 242 27
The effect of
somatostatin
on hepatocarcinogenesis induced by N-nitrosomorpholine (NNM) was investigated in male Sprague-Dawley rats. Rats were given drinking water containing NNM for 8 weeks and s.c. injections of 200 micrograms/kg body wt of
somatostatin
every other day from the beginning of the experiment until the end of week 16. Pre-neoplastic and neoplastic lesions staining for
gamma-glutamyl transpeptidase
(
GGT
) or placental type glutathione-S-transferase (GST-P) were examined histochemically. Administration of
somatostatin
for 16 weeks resulted in significant reduction in the percentage volume of
GGT
-positive and GST-P-positive lesions. The incidence, number and size of hepatocellular carcinomas were significantly less in rats treated with
somatostatin
than in untreated rats. Administration of
somatostatin
significantly decreased the labeling indices of pre-neoplastic lesions and adjacent liver. These findings indicate that
somatostatin
inhibits hepatocarcinogenesis and that this effect may be related to its effect in decreasing cell proliferation in pre-neoplastic lesions.
...
PMID:Inhibition by somatostatin of hepatocarcinogenesis induced by N-nitrosomorpholine in Sprague-Dawley rats. 790 4